Approaches and Challenges for Biosensors for Acute and Chronic Heart Failure

Biosensors (Basel). 2023 Feb 16;13(2):282. doi: 10.3390/bios13020282.

Abstract

Heart failure (HF) is a cardiovascular disease defined by several symptoms that occur when the heart cannot supply the blood needed by the tissues. HF, which affects approximately 64 million people worldwide and whose incidence and prevalence are increasing, has an important place in terms of public health and healthcare costs. Therefore, developing and enhancing diagnostic and prognostic sensors is an urgent need. Using various biomarkers for this purpose is a significant breakthrough. It is possible to classify the biomarkers used in HF: associated with myocardial and vascular stretch (B-type natriuretic peptide (BNP), N-terminal proBNP and troponin), related to neurohormonal pathways (aldosterone and plasma renin activity), and associated with myocardial fibrosis and hypertrophy (soluble suppression of tumorigenicity 2 and galactin 3). There is an increasing demand for the design of fast, portable, and low-cost biosensing devices for the biomarkers related to HF. Biosensors play a significant role in early diagnosis as an alternative to time-consuming and expensive laboratory analysis. In this review, the most influential and novel biosensor applications for acute and chronic HF will be discussed in detail. These studies will be evaluated in terms of advantages, disadvantages, sensitivity, applicability, user-friendliness, etc.

Keywords: biomarkers; biosensors; detection; diagnosis; heart failure.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Biosensing Techniques*
  • Cardiovascular Diseases*
  • Chronic Disease
  • Heart Failure*
  • Humans
  • Peptide Fragments
  • Prognosis

Substances

  • Biomarkers
  • Peptide Fragments

Grants and funding

This research received no external funding.